Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-05-13

AUTHORS

A. A. N. Giagounidis, U. Germing, C. Strupp, B. Hildebrandt, M. Heinsch, C. Aul

ABSTRACT

The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated del(5q31) and those with one single additional chromosomal abnormality achieve hematological and cytogenetic remissions with lenalidomide therapy. Whether this translates into improved overall survival of the patient population is unclear. We analysed data of 25 patients with myelodysplastic syndrome and complex chromosomal abnormalities including del(5q31) and show that their median survival is between 7 and 8 months, irrespective of the medullary blast count. Furthermore, we present data of a patient with complex karyotypic anomalies inclusive of del(5q31) treated with lenalidomide who achieved complete cytogenetic remission. This cytogenetic remission was diagnosed after 6 months, and the hematological response is ongoing at 9 months of therapy at a dose of 5 mg p.o. daily. We conclude that lenalidomide has the potential to induce sustained hematological and cytogenetic remissions in the poor prognosis MDS subgroup of del(5q31) patients with complex chromosomal anomalies and that this is likely to improve overall survival. More... »

PAGES

569-571

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-005-1054-0

DOI

http://dx.doi.org/10.1007/s00277-005-1054-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1002613856

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15891887


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromosome Aberrations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromosome Deletion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromosomes, Human, Pair 5", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Karyotyping", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lenalidomide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myelodysplastic Syndromes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Remission Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thalidomide", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medizinische Klinik II, St. Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.459950.4", 
          "name": [
            "Medizinische Klinik II, St. Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Giagounidis", 
        "givenName": "A. A. N.", 
        "id": "sg:person.01164215515.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164215515.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr H\u00e4matologie, Onkologie und klinische Immunologie, Heinrich-Heine Universit\u00e4t D\u00fcsseldorf, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie und klinische Immunologie, Heinrich-Heine Universit\u00e4t D\u00fcsseldorf, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germing", 
        "givenName": "U.", 
        "id": "sg:person.01362464041.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr H\u00e4matologie, Onkologie und klinische Immunologie, Heinrich-Heine Universit\u00e4t D\u00fcsseldorf, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Klinik f\u00fcr H\u00e4matologie, Onkologie und klinische Immunologie, Heinrich-Heine Universit\u00e4t D\u00fcsseldorf, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Strupp", 
        "givenName": "C.", 
        "id": "sg:person.01001653715.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut f\u00fcr Humangenetik und Anthropologie, Heinrich-Heine Universit\u00e4t D\u00fcsseldorf, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany", 
          "id": "http://www.grid.ac/institutes/grid.411327.2", 
          "name": [
            "Institut f\u00fcr Humangenetik und Anthropologie, Heinrich-Heine Universit\u00e4t D\u00fcsseldorf, Moorenstr. 5, 40225, D\u00fcsseldorf, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hildebrandt", 
        "givenName": "B.", 
        "id": "sg:person.01320675564.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medizinische Klinik II, St. Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.459950.4", 
          "name": [
            "Medizinische Klinik II, St. Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Heinsch", 
        "givenName": "M.", 
        "id": "sg:person.0702245567.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702245567.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medizinische Klinik II, St. Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.459950.4", 
          "name": [
            "Medizinische Klinik II, St. Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aul", 
        "givenName": "C.", 
        "id": "sg:person.01300444115.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300444115.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00277-005-1027-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049156023", 
          "https://doi.org/10.1007/s00277-005-1027-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2402894", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001004907", 
          "https://doi.org/10.1038/sj.leu.2402894"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1323", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044837763", 
          "https://doi.org/10.1038/nrc1323"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2403189", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017741193", 
          "https://doi.org/10.1038/sj.leu.2403189"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-05-13", 
    "datePublishedReg": "2005-05-13", 
    "description": "The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated del(5q31) and those with one single additional chromosomal abnormality achieve hematological and cytogenetic remissions with lenalidomide therapy. Whether this translates into improved overall survival of the patient population is unclear. We analysed data of 25 patients with myelodysplastic syndrome and complex chromosomal abnormalities including del(5q31) and show that their median survival is between 7 and 8 months, irrespective of the medullary blast count. Furthermore, we present data of a patient with complex karyotypic anomalies inclusive of del(5q31) treated with lenalidomide who achieved complete cytogenetic remission. This cytogenetic remission was diagnosed after 6 months, and the hematological response is ongoing at 9 months of therapy at a dose of 5\u00a0mg p.o. daily. We conclude that lenalidomide has the potential to induce sustained hematological and cytogenetic remissions in the poor prognosis MDS subgroup of del(5q31) patients with complex chromosomal anomalies and that this is likely to improve overall survival.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-005-1054-0", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "84"
      }
    ], 
    "keywords": [
      "cytogenetic remission", 
      "chromosomal abnormalities", 
      "overall survival", 
      "myelodysplastic syndrome", 
      "medullary blast count", 
      "months of therapy", 
      "survival of patients", 
      "prognosis of patients", 
      "complete cytogenetic remission", 
      "additional chromosomal abnormalities", 
      "complex chromosomal anomaly", 
      "complex chromosomal abnormalities", 
      "MDS subgroups", 
      "lenalidomide therapy", 
      "median survival", 
      "blast count", 
      "favorable prognosis", 
      "patient population", 
      "patient subgroups", 
      "hematological response", 
      "patients", 
      "remission", 
      "karyotypic anomalies", 
      "chromosomal anomalies", 
      "complex karyotype", 
      "lenalidomide", 
      "abnormalities", 
      "survival", 
      "months", 
      "prognosis", 
      "syndrome", 
      "therapy", 
      "possible role", 
      "subgroups", 
      "dose", 
      "count", 
      "population", 
      "karyotype", 
      "anomalies", 
      "response", 
      "data", 
      "MD", 
      "role", 
      "addition", 
      "potential"
    ], 
    "name": "Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup", 
    "pagination": "569-571", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1002613856"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-005-1054-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15891887"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-005-1054-0", 
      "https://app.dimensions.ai/details/publication/pub.1002613856"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_410.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-005-1054-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-1054-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-1054-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-1054-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-005-1054-0'


 

This table displays all metadata directly associated to this object as RDF triples.

222 TRIPLES      21 PREDICATES      89 URIs      77 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-005-1054-0 schema:about N0b442bc4be5a435fb0248a6d9261cfbf
2 N13749f3ee2404ac8a2420cafced709ae
3 N33260064ae2842cd8f135bb09fa46c06
4 N45c4834d01e34a6faf0df06fc98bdb0b
5 N466ba55312d543dd829d41436e57651e
6 N5087dc2ac9264c5b9499eeeb731c1a6c
7 N53c02608effc4453a74814a818643b5a
8 N59a709f839b14eff900d5ce2c61e8075
9 N6301b1eff74a44f6989fa0c26dc9b33f
10 N8fcdf97a31954922a32e428949e921c1
11 Na448b5d8d4a84920896280659d961bc3
12 Nd6fbc9fff4604e0e9943d6726f1076c5
13 Ne9d0989ad7404e079dc0e3f3504cab41
14 Nee0e5d75368a4f46b926ecc8dc45108e
15 Nf5b5e9ac5ba8490eb631a0aea3b720b0
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N13f135a337214e3aac599555814e71bc
19 schema:citation sg:pub.10.1007/s00277-005-1027-3
20 sg:pub.10.1038/nrc1323
21 sg:pub.10.1038/sj.leu.2402894
22 sg:pub.10.1038/sj.leu.2403189
23 schema:datePublished 2005-05-13
24 schema:datePublishedReg 2005-05-13
25 schema:description The survival of patients with myelodysplastic syndromes is strongly affected by chromosomal abnormalities. Patients with an isolated del(5q31) have a favourable prognosis that worsens with the addition of another chromosomal abnormality. It has been reported that both patients with isolated del(5q31) and those with one single additional chromosomal abnormality achieve hematological and cytogenetic remissions with lenalidomide therapy. Whether this translates into improved overall survival of the patient population is unclear. We analysed data of 25 patients with myelodysplastic syndrome and complex chromosomal abnormalities including del(5q31) and show that their median survival is between 7 and 8 months, irrespective of the medullary blast count. Furthermore, we present data of a patient with complex karyotypic anomalies inclusive of del(5q31) treated with lenalidomide who achieved complete cytogenetic remission. This cytogenetic remission was diagnosed after 6 months, and the hematological response is ongoing at 9 months of therapy at a dose of 5 mg p.o. daily. We conclude that lenalidomide has the potential to induce sustained hematological and cytogenetic remissions in the poor prognosis MDS subgroup of del(5q31) patients with complex chromosomal anomalies and that this is likely to improve overall survival.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N6ab92a2e033f4e69972902f294e917e0
29 Na1af8894becb42d89827687aaed60e02
30 sg:journal.1358129
31 schema:keywords MD
32 MDS subgroups
33 abnormalities
34 addition
35 additional chromosomal abnormalities
36 anomalies
37 blast count
38 chromosomal abnormalities
39 chromosomal anomalies
40 complete cytogenetic remission
41 complex chromosomal abnormalities
42 complex chromosomal anomaly
43 complex karyotype
44 count
45 cytogenetic remission
46 data
47 dose
48 favorable prognosis
49 hematological response
50 karyotype
51 karyotypic anomalies
52 lenalidomide
53 lenalidomide therapy
54 median survival
55 medullary blast count
56 months
57 months of therapy
58 myelodysplastic syndrome
59 overall survival
60 patient population
61 patient subgroups
62 patients
63 population
64 possible role
65 potential
66 prognosis
67 prognosis of patients
68 remission
69 response
70 role
71 subgroups
72 survival
73 survival of patients
74 syndrome
75 therapy
76 schema:name Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup
77 schema:pagination 569-571
78 schema:productId N3ca5b3a88d534a2c98c5ebea887dab46
79 N7970fcd5031543ac8a6d68677c3fdb2b
80 Nb918989c7aa44afe8f930b043f26c886
81 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002613856
82 https://doi.org/10.1007/s00277-005-1054-0
83 schema:sdDatePublished 2022-08-04T16:56
84 schema:sdLicense https://scigraph.springernature.com/explorer/license/
85 schema:sdPublisher N39ed87d2335f4f09b2c7aaaa8618ac27
86 schema:url https://doi.org/10.1007/s00277-005-1054-0
87 sgo:license sg:explorer/license/
88 sgo:sdDataset articles
89 rdf:type schema:ScholarlyArticle
90 N0b442bc4be5a435fb0248a6d9261cfbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Lenalidomide
92 rdf:type schema:DefinedTerm
93 N13749f3ee2404ac8a2420cafced709ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Survival Rate
95 rdf:type schema:DefinedTerm
96 N13f135a337214e3aac599555814e71bc rdf:first sg:person.01164215515.10
97 rdf:rest N14a80bc12c164335aa3ad75c828b9fd5
98 N14a80bc12c164335aa3ad75c828b9fd5 rdf:first sg:person.01362464041.20
99 rdf:rest Na80423670e1a4cd7badce06b4b869c16
100 N33260064ae2842cd8f135bb09fa46c06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Myelodysplastic Syndromes
102 rdf:type schema:DefinedTerm
103 N39ed87d2335f4f09b2c7aaaa8618ac27 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 N3ca5b3a88d534a2c98c5ebea887dab46 schema:name dimensions_id
106 schema:value pub.1002613856
107 rdf:type schema:PropertyValue
108 N45c4834d01e34a6faf0df06fc98bdb0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Aged, 80 and over
110 rdf:type schema:DefinedTerm
111 N466ba55312d543dd829d41436e57651e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Karyotyping
113 rdf:type schema:DefinedTerm
114 N5087dc2ac9264c5b9499eeeb731c1a6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Chromosomes, Human, Pair 5
116 rdf:type schema:DefinedTerm
117 N53c02608effc4453a74814a818643b5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Remission Induction
119 rdf:type schema:DefinedTerm
120 N59a709f839b14eff900d5ce2c61e8075 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Humans
122 rdf:type schema:DefinedTerm
123 N6301b1eff74a44f6989fa0c26dc9b33f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Chromosome Aberrations
125 rdf:type schema:DefinedTerm
126 N6ab92a2e033f4e69972902f294e917e0 schema:volumeNumber 84
127 rdf:type schema:PublicationVolume
128 N7970fcd5031543ac8a6d68677c3fdb2b schema:name doi
129 schema:value 10.1007/s00277-005-1054-0
130 rdf:type schema:PropertyValue
131 N8fcdf97a31954922a32e428949e921c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Thalidomide
133 rdf:type schema:DefinedTerm
134 N94095903040c482bacddfd4c49b55f8e rdf:first sg:person.0702245567.12
135 rdf:rest N9b614d29ecc348c8be933e025aa48fac
136 N9603b6239c04409a84a3222aa83b9972 rdf:first sg:person.01320675564.15
137 rdf:rest N94095903040c482bacddfd4c49b55f8e
138 N9b614d29ecc348c8be933e025aa48fac rdf:first sg:person.01300444115.40
139 rdf:rest rdf:nil
140 Na1af8894becb42d89827687aaed60e02 schema:issueNumber 9
141 rdf:type schema:PublicationIssue
142 Na448b5d8d4a84920896280659d961bc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Prognosis
144 rdf:type schema:DefinedTerm
145 Na80423670e1a4cd7badce06b4b869c16 rdf:first sg:person.01001653715.11
146 rdf:rest N9603b6239c04409a84a3222aa83b9972
147 Nb918989c7aa44afe8f930b043f26c886 schema:name pubmed_id
148 schema:value 15891887
149 rdf:type schema:PropertyValue
150 Nd6fbc9fff4604e0e9943d6726f1076c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Aged
152 rdf:type schema:DefinedTerm
153 Ne9d0989ad7404e079dc0e3f3504cab41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Middle Aged
155 rdf:type schema:DefinedTerm
156 Nee0e5d75368a4f46b926ecc8dc45108e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Chromosome Deletion
158 rdf:type schema:DefinedTerm
159 Nf5b5e9ac5ba8490eb631a0aea3b720b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Adult
161 rdf:type schema:DefinedTerm
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
166 schema:name Oncology and Carcinogenesis
167 rdf:type schema:DefinedTerm
168 sg:journal.1358129 schema:issn 0939-5555
169 1432-0584
170 schema:name Annals of Hematology
171 schema:publisher Springer Nature
172 rdf:type schema:Periodical
173 sg:person.01001653715.11 schema:affiliation grid-institutes:grid.411327.2
174 schema:familyName Strupp
175 schema:givenName C.
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001653715.11
177 rdf:type schema:Person
178 sg:person.01164215515.10 schema:affiliation grid-institutes:grid.459950.4
179 schema:familyName Giagounidis
180 schema:givenName A. A. N.
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164215515.10
182 rdf:type schema:Person
183 sg:person.01300444115.40 schema:affiliation grid-institutes:grid.459950.4
184 schema:familyName Aul
185 schema:givenName C.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300444115.40
187 rdf:type schema:Person
188 sg:person.01320675564.15 schema:affiliation grid-institutes:grid.411327.2
189 schema:familyName Hildebrandt
190 schema:givenName B.
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320675564.15
192 rdf:type schema:Person
193 sg:person.01362464041.20 schema:affiliation grid-institutes:grid.411327.2
194 schema:familyName Germing
195 schema:givenName U.
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20
197 rdf:type schema:Person
198 sg:person.0702245567.12 schema:affiliation grid-institutes:grid.459950.4
199 schema:familyName Heinsch
200 schema:givenName M.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702245567.12
202 rdf:type schema:Person
203 sg:pub.10.1007/s00277-005-1027-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049156023
204 https://doi.org/10.1007/s00277-005-1027-3
205 rdf:type schema:CreativeWork
206 sg:pub.10.1038/nrc1323 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044837763
207 https://doi.org/10.1038/nrc1323
208 rdf:type schema:CreativeWork
209 sg:pub.10.1038/sj.leu.2402894 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001004907
210 https://doi.org/10.1038/sj.leu.2402894
211 rdf:type schema:CreativeWork
212 sg:pub.10.1038/sj.leu.2403189 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017741193
213 https://doi.org/10.1038/sj.leu.2403189
214 rdf:type schema:CreativeWork
215 grid-institutes:grid.411327.2 schema:alternateName Institut für Humangenetik und Anthropologie, Heinrich-Heine Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
216 Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
217 schema:name Institut für Humangenetik und Anthropologie, Heinrich-Heine Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
218 Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany
219 rdf:type schema:Organization
220 grid-institutes:grid.459950.4 schema:alternateName Medizinische Klinik II, St. Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany
221 schema:name Medizinische Klinik II, St. Johannes Hospital, An der Abtei 7-11, 47166, Duisburg, Germany
222 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...